Similar articles for PMID: 28189201

Year	Number of Results
2010	2
2011	4
2012	7
2013	7
2014	21
2015	25
2016	39
2017	22
2018	20
2019	24
2020	10
2021	3
2022	2
2023	3
2024	0

1

Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib.

Nishino M, Sacher AG, Gandhi L, Chen Z, Akbay E, Fedorov A, Westin CF, Hatabu H, Johnson BE, Hammerman P, Wong KK. Nishino M, et al. Eur J Radiol. 2017 Mar;88:15-20. doi: 10.1016/j.ejrad.2016.12.028. Epub 2016 Dec 26. Eur J Radiol. 2017. PMID: 28189201 Free PMC article.

2

Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.

Ou SH. Ou SH. Drug Des Devel Ther. 2011;5:471-85. doi: 10.2147/DDDT.S19045. Epub 2011 Nov 23. Drug Des Devel Ther. 2011. PMID: 22162641 Free PMC article. Review.

3

Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.

Watanabe S, Hayashi H, Okamoto K, Fujiwara K, Hasegawa Y, Kaneda H, Tanaka K, Takeda M, Nakagawa K. Watanabe S, et al. Clin Lung Cancer. 2016 Nov;17(6):528-534. doi: 10.1016/j.cllc.2016.05.001. Epub 2016 May 18. Clin Lung Cancer. 2016. PMID: 27318655

4

Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.

Casaluce F, Sgambato A, Sacco PC, Palazzolo G, Maione P, Rossi A, Ciardiello F, Gridelli C. Casaluce F, et al. Curr Clin Pharmacol. 2016;11(2):77-87. doi: 10.2174/1574884711666160502124134. Curr Clin Pharmacol. 2016. PMID: 27138017 Review.

5

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, Kulig K, Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafrate AJ, Camidge DR. Shaw AT, et al. Lancet Oncol. 2011 Oct;12(11):1004-12. doi: 10.1016/S1470-2045(11)70232-7. Epub 2011 Sep 18. Lancet Oncol. 2011. PMID: 21933749 Free PMC article.

6

Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.

Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR. Gettinger SN, et al. Lancet Oncol. 2016 Dec;17(12):1683-1696. doi: 10.1016/S1470-2045(16)30392-8. Epub 2016 Nov 8. Lancet Oncol. 2016. PMID: 27836716 Clinical Trial.

7

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.

Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, Zhou C, Shreeve SM, Selaru P, Polli A, Schnell P, Wilner KD, Wiltshire R, Camidge DR, Crinò L. Costa DB, et al. J Clin Oncol. 2015 Jun 10;33(17):1881-8. doi: 10.1200/JCO.2014.59.0539. Epub 2015 Jan 26. J Clin Oncol. 2015. PMID: 25624436 Free PMC article.

8

Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.

Ou SH, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ. Ou SH, et al. Oncologist. 2012;17(11):1351-75. doi: 10.1634/theoncologist.2012-0311. Epub 2012 Sep 18. Oncologist. 2012. PMID: 22989574 Free PMC article. Review.

9

Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.

Ito K, Hataji O, Kobayashi H, Fujiwara A, Yoshida M, D'Alessandro-Gabazza CN, Itani H, Tanigawa M, Ikeda T, Fujiwara K, Fujimoto H, Kobayashi T, Gabazza EC, Taguchi O, Yamamoto N. Ito K, et al. J Thorac Oncol. 2017 Feb;12(2):390-396. doi: 10.1016/j.jtho.2016.07.022. Epub 2016 Aug 4. J Thorac Oncol. 2017. PMID: 27498387 Free article.

10

Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib.

Hida T, Dahlberg SE, Lydon CA, Hatabu H, Johnson BE, Awad MM, Nishino M. Hida T, et al. J Thorac Imaging. 2020 Mar;35(2):101-107. doi: 10.1097/RTI.0000000000000413. J Thorac Imaging. 2020. PMID: 30985604

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

171 results

Results by year